SequelSEC

RenovoRx, Inc. RNXT

Pharmaceutical Preparations · CIK 0001574094 · Fiscal year ends 1231

Revenue
$1.98M
Fiscal year ended 2026-06-30
Operating income
-$13.54M
Fiscal year ended 2026-06-30
Free cash flow
-$11.94M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$26.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-06-30
Float per share$0.59Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue618.6×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity5.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2024-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth2511.6%98th
CapEx / revenue0.2%13th
FCF margin-977.3%24th
SBC / revenue112.8%70th
Net margin-994.5%31th
Operating margin-1114.0%32th
R&D / revenue558.2%67th
Current ratio4.02x53th
Gross margin70.9%48th

RenovoRx, Inc. (RNXT) reported revenue of $1.98M and net income of -$12.28M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from RenovoRx, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

RenovoRx, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.98M
Cost of revenue$308.00K
Gross profit$1.67M
Operating income-$13.54M
Net income-$12.28M
Research & development$5.61M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$2.00K
Diluted EPSUnavailable
Selling, general & administrative$9.59M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

RenovoRx, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$9.48M
Total assets$11.47M
Current assets$10.81M
Total liabilities$2.49M
Current liabilities$1.88M
Total equity incl. NCI$8.98M
Temporary (mezzanine) equityUnavailable
Inventory$383.00K
Accounts receivable$480.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$866.00K

Cash flow

RenovoRx, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$11.87M
Capital expenditures$71.00K
Investing cash flow-$71.00K
Financing cash flow$9.10M
Net change in cash-$2.84M
Stock-based compensation$1.52M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

RenovoRx, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$11.94M
Gross margin84.4%
Operating margin-685.2%
FCF margin-604.1%
SBC / revenue77.0%
Current ratio5.74x
Revenue YoY growthUnavailable
Net margin-621.7%
R&D / revenue284.1%
CapEx / revenue3.6%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RNXT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.